post by Bill Gardner
Although the Canadian health system differs greatly from the US system, it faces many similar problems:
Canada faces a dual challenge in the research-to-practice continuum, often referred to as the two "Death Valleys" in the health care landscape. Valley 1 refers to the decreased capacity to translate the results of discoveries generated by basic biomedical research in the laboratory to the bedside or careside as well as to successfully commercialize health discoveries. This negatively impacts Canada's clinical research and knowledge base and its international competitiveness. Valley 2 refers to the limited capacity to synthesize, disseminate and integrate research results more broadly into clinical practice and health care decision-making. These two valleys must be bridged if Canada is to bring evidence to bear to enhance health outcomes and ensure a sustainable health care system.
- To strengthen organizational, regulatory and financial support for clinical studies in Canada and enhance patient and clinician engagement in these studies; and
- To improve processes for the early identification of best practices, expedite their development and harmonization into guidelines for patient care and support their adoption by clinicians, caregivers and patients.”
This similar to the strategy for comparative effectiveness research (CER) promoted by the US Patient-Centered Outcomes Research Institute (PCORI). Many conservatives oppose the PCORI, which was established as part of President Obama's Affordable Care Act. I've never understood why, but I urge them to reconsider their views on PCORI and CER. The Canadian strategy, after all, is the policy of the Conservative government of Prime Minister Stephen Harper.